News from the FDA/CDC

FDA approves first-ever OTC erectile dysfunction gel


 

A topical gel that may work faster than erectile dysfunction pills has been approved for over-the-counter use in the United States. The gel, which can help users get an erection within 10 minutes, is already available without a prescription in Europe.

The Food and Drug Administration has approved the drug, called Eroxon, noting that it is a first-of-its-kind treatment. Eroxon is made by the British pharmaceutical company Futura Medical, which specializes in drugs that are given through the skin.

FDA icon

According to the product’s leaflet, Eroxon “stimulates blood flow in the penis through a unique physical cooling then warming effect, helping you get and keep an erection hard enough for sex.” The company said on the product’s website that 65% of people who used the drug were able to have sex.

A company spokesperson told CNN that the price of the product has not been set in the United States, but it costs the equivalent of about $31 in the United Kingdom. Futura Medical has not announced when it will be available in the United States.

Harvard Health reports that 30 million people in the United States have erectile dysfunction, which means a person cannot get an erection at all or one firm enough to have sex. The disorder is often linked to other physical or mental health problems, such as heart problems or clogged arteries.

Erectile dysfunction affects 1% of men in their 40s, 17% of men in their 60s, and nearly 50% of men who are age 75 or older, according to Harvard Health.

A version of this article originally appeared on WebMD.com.

Recommended Reading

Testosterone ranges for young men could help classify deficiency
MDedge Endocrinology
A hormone that can predict male long-term health
MDedge Endocrinology
Getting testosterone online is easy. Solid advice, not so much
MDedge Endocrinology
Can a Mediterranean diet ease depression in young men?
MDedge Endocrinology
New osteoporosis guideline says start with a bisphosphonate
MDedge Endocrinology
Can a hormone shot rescue low libido?
MDedge Endocrinology
Three surprising studies on exercise restriction and an exercise sweet spot
MDedge Endocrinology
Factors linked with increased VTE risk in COVID outpatients
MDedge Endocrinology
COVID can mimic prostate cancer symptoms
MDedge Endocrinology
Prostate cancer drug shortage leaves some with uncertainty
MDedge Endocrinology